L Arthur Hewitt
Overview
Explore the profile of L Arthur Hewitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hauser R, Favit A, Hewitt L, Lindsten A, Gorny S, Kymes S, et al.
Neurol Ther
. 2022 Feb;
11(1):459-469.
PMID: 35107750
Introduction: Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa...
2.
Francois C, Germain N, Majewska R, Taieb V, Hewitt L, Kymes S
J Mark Access Health Policy
. 2022 Jan;
10(1):2010961.
PMID: 35035792
Background: Symptoms of neurogenic orthostatic hypotension (nOH), including lightheadedness/dizziness, presyncope, syncope, and falls, can lead to impaired functional ability and reduced quality of life. Because the severity and frequency of...
3.
Hewitt L, Lindsten A, Gorny S, Karnik-Henry M, Kymes S, Favit A
Health Sci Rep
. 2021 Feb;
4(1):e227.
PMID: 33521332
Background And Aims: Patients with neurogenic orthostatic hypotension (nOH) due to autonomic dysfunction may also experience supine hypertension (defined as supine systolic blood pressure [SBP] ≥140 mmHg). Because pressor agents...
4.
Gibson J, Hunter C, Hewitt L
Neurol Ther
. 2020 Jul;
9(2):205-211.
PMID: 32720118
Neurogenic orthostatic hypotension (nOH) is a sustained fall in blood pressure upon standing that frequently affects patients with neurodegenerative diseases (e.g., Parkinson disease) and manifests with symptoms such as lightheadedness...
5.
Hauser R, Biaggioni I, Hewitt L, Vernino S
Mov Disord Clin Pract
. 2019 Jan;
5(6):627-634.
PMID: 30637284
Introduction: Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end-organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for...
6.
Claassen D, Adler C, Hewitt L, Gibbons C
BMC Neurol
. 2018 Aug;
18(1):125.
PMID: 30144800
Background: Neurogenic orthostatic hypotension (nOH) results from impaired vasoconstriction due to dysfunction of the autonomic nervous system and is commonly associated with Parkinson disease (PD), multiple system atrophy (MSA), and...
7.
Chen J, Hewitt L
Drugs R D
. 2018 Feb;
18(1):77-86.
PMID: 29392574
Background: Droxidopa is an oral prodrug of norepinephrine approved for the treatment of symptomatic neurogenic orthostatic hypotension. This two-part, randomized, crossover study evaluated the 24-h pharmacokinetic profile of droxidopa in...
8.
White W, Hewitt L, Mehdirad A
Clin Pharmacol Drug Dev
. 2017 Oct;
7(3):332-340.
PMID: 29024579
A double-blind, 4-period crossover study (NCT01327066) was conducted to assess the effect of the novel norepinephrine prodrug droxidopa on the QT interval in in healthy subjects. Subjects were randomized to...
9.
Biaggioni I, Hewitt L, Rowse G, Kaufmann H
BMC Neurol
. 2017 May;
17(1):90.
PMID: 28494751
Background: Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies. We performed safety and...
10.
White W, Hauser R, Rowse G, Ziemann A, Hewitt L
Am J Cardiol
. 2017 Feb;
119(7):1111-1115.
PMID: 28159196
The norepinephrine prodrug droxidopa improves symptoms of neurogenic orthostatic hypotension, a condition that is associated with diseases of neurogenic autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure)....